Abbott Expects To Resume Shipments Of Recalled MitraClip In Several Months
This article was originally published in The Gray Sheet
Executive Summary
Abbott expects it will take several months to resume shipments of its MitraClip transcatheter mitral valve repair system following a voluntary global recall, but the firm says the recall is not likely to impact anticipated U.S. approval of the device later this year.